Limits...
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer

View Article: PubMed Central - PubMed

ABSTRACT

Lung adenosquamous cell carcinomas (ASCs) is a rare variant of NSCLC with a poorer prognosis and fewer treatment option than the more common variants. PD-L1 expression is reported to be the predictor of clinical response in trials of NSCLC. In our study, PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP263), and PD-L1 mRNA expression was evaluated via in situ hybridization. This study included 51 ASCs, 133 lung adenocarcinomas, and 83 lung squamous cell carcinomas (SCC). Similar results were obtained for PD-L1 expression measured at the mRNA and protein level (k coefficient, 0.851, P = 1.000). PD-L1 expression was significantly higher in the squamous versus glandular component of the 36 ASCs in which the components were analyzed separately. The PD-L1 expression rate was similar in the squamous cell component of ASCs and lung SCC (38.89% vs. 28.92%, P = 0.293), so does the adenocarcinoma component of ASCs and lung adenocarcinomas (11.11% vs 13.53%, P = 1.000). PD-L1 expression correlated significantly with lymphovascular invasion (P = 0.016), but not with EGFR, KRAS, and ALK mutations in lung ASCs. Anit-PD-L1 is a promising treatment option in lung ASC cases in which PD-L1 upregulated and EGFR mutations are present.

No MeSH data available.


Representative results of PD-L1 expression in lung ASC.(a) Positive results of PD-L1 examined via immunohistochemistry method. (x100) (b) Negative results of PD-L1 examined via immunohistochemistry method. (x100) (c) Positive results of PD-L1 examined via RNA in situ hybridization method. (x100) (d) Negative results of PD-L1 examined via RNA in situ hybridization method. (x100).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5384250&req=5

f1: Representative results of PD-L1 expression in lung ASC.(a) Positive results of PD-L1 examined via immunohistochemistry method. (x100) (b) Negative results of PD-L1 examined via immunohistochemistry method. (x100) (c) Positive results of PD-L1 examined via RNA in situ hybridization method. (x100) (d) Negative results of PD-L1 examined via RNA in situ hybridization method. (x100).

Mentions: Of the 51 lung ASCs in this study, 36 had separable glandular and squamous components that were evaluated independently. Consequently, a total of 87 tissue samples were examined. PD-L1 expression was detected by IHC and ISH in 39.22% and 37.25% of the lung ASCs, respectively. There was no differences between the two techniques in terms of which tumors were negative and which were positive. Representative IHC and RNA ISH results are shown in Fig. 1. The agreement between the IHC and mRNA ISH results was nearly perfect (91.3%, 179/196), with a κ –coefficient of 0.851. There was no significant difference between the two methods according to the McNemar-Bowker test (P = 1.000) (Table 1).


PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer
Representative results of PD-L1 expression in lung ASC.(a) Positive results of PD-L1 examined via immunohistochemistry method. (x100) (b) Negative results of PD-L1 examined via immunohistochemistry method. (x100) (c) Positive results of PD-L1 examined via RNA in situ hybridization method. (x100) (d) Negative results of PD-L1 examined via RNA in situ hybridization method. (x100).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5384250&req=5

f1: Representative results of PD-L1 expression in lung ASC.(a) Positive results of PD-L1 examined via immunohistochemistry method. (x100) (b) Negative results of PD-L1 examined via immunohistochemistry method. (x100) (c) Positive results of PD-L1 examined via RNA in situ hybridization method. (x100) (d) Negative results of PD-L1 examined via RNA in situ hybridization method. (x100).
Mentions: Of the 51 lung ASCs in this study, 36 had separable glandular and squamous components that were evaluated independently. Consequently, a total of 87 tissue samples were examined. PD-L1 expression was detected by IHC and ISH in 39.22% and 37.25% of the lung ASCs, respectively. There was no differences between the two techniques in terms of which tumors were negative and which were positive. Representative IHC and RNA ISH results are shown in Fig. 1. The agreement between the IHC and mRNA ISH results was nearly perfect (91.3%, 179/196), with a κ –coefficient of 0.851. There was no significant difference between the two methods according to the McNemar-Bowker test (P = 1.000) (Table 1).

View Article: PubMed Central - PubMed

ABSTRACT

Lung adenosquamous cell carcinomas (ASCs) is a rare variant of NSCLC with a poorer prognosis and fewer treatment option than the more common variants. PD-L1 expression is reported to be the predictor of clinical response in trials of NSCLC. In our study, PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP263), and PD-L1 mRNA expression was evaluated via in situ hybridization. This study included 51 ASCs, 133 lung adenocarcinomas, and 83 lung squamous cell carcinomas (SCC). Similar results were obtained for PD-L1 expression measured at the mRNA and protein level (k coefficient, 0.851, P = 1.000). PD-L1 expression was significantly higher in the squamous versus glandular component of the 36 ASCs in which the components were analyzed separately. The PD-L1 expression rate was similar in the squamous cell component of ASCs and lung SCC (38.89% vs. 28.92%, P = 0.293), so does the adenocarcinoma component of ASCs and lung adenocarcinomas (11.11% vs 13.53%, P = 1.000). PD-L1 expression correlated significantly with lymphovascular invasion (P = 0.016), but not with EGFR, KRAS, and ALK mutations in lung ASCs. Anit-PD-L1 is a promising treatment option in lung ASC cases in which PD-L1 upregulated and EGFR mutations are present.

No MeSH data available.